NDRA vs. CHFS, NUWE, HSDT, TIVC, VRAYQ, VIVE, IRIX, ECOR, MDT, and MASI
Should you be buying ENDRA Life Sciences stock or one of its competitors? The main competitors of ENDRA Life Sciences include Nuwellis (CHFS), Nuwellis (NUWE), Helius Medical Technologies (HSDT), Tivic Health Systems (TIVC), ViewRay (VRAYQ), Viveve Medical (VIVE), IRIDEX (IRIX), electroCore (ECOR), Medtronic (MDT), and Masimo (MASI).
ENDRA Life Sciences (NASDAQ:NDRA) and Nuwellis (NASDAQ:CHFS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
ENDRA Life Sciences has higher earnings, but lower revenue than Nuwellis. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
In the previous week, ENDRA Life Sciences had 3 more articles in the media than Nuwellis. MarketBeat recorded 3 mentions for ENDRA Life Sciences and 0 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.00 beat ENDRA Life Sciences' score of -0.45 indicating that Nuwellis is being referred to more favorably in the news media.
ENDRA Life Sciences presently has a consensus price target of $8.00, indicating a potential upside of 7,820.79%. Given ENDRA Life Sciences' higher probable upside, research analysts plainly believe ENDRA Life Sciences is more favorable than Nuwellis.
ENDRA Life Sciences has a net margin of 0.00% compared to Nuwellis' net margin of -254.26%. Nuwellis' return on equity of -173.61% beat ENDRA Life Sciences' return on equity.
Nuwellis received 88 more outperform votes than ENDRA Life Sciences when rated by MarketBeat users. Likewise, 69.53% of users gave Nuwellis an outperform vote while only 62.77% of users gave ENDRA Life Sciences an outperform vote.
ENDRA Life Sciences has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Nuwellis has a beta of 1.55, suggesting that its share price is 55% more volatile than the S&P 500.
1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 65.1% of Nuwellis shares are held by institutional investors. 4.8% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 0.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Nuwellis beats ENDRA Life Sciences on 9 of the 16 factors compared between the two stocks.
Get ENDRA Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ENDRA Life Sciences Competitors List
Related Companies and Tools
